New HIV vaccine trial aims to spark key antibodies in infected individuals

NCT ID NCT06006546

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times

Summary

This early-stage study tests whether an experimental vaccine can help people with HIV produce special antibodies called VRC01, which may fight the virus more effectively. About 35 participants will receive the vaccine and temporarily pause their regular HIV medication to see if the vaccine can control the virus. The main goal is to check safety and measure immune responses.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atlanta- Ponce

    Atlanta, Georgia, 30303, United States

  • BIDMC

    Boston, Massachusetts, 02215, United States

  • Birmingham

    Birmingham, Alabama, 35294-2170, United States

  • Columbia P&S CRS Site#30329

    New York, New York, 10032, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • Seattle Vaccine and Prevention CRS (Site # 30331)

    Seattle, Washington, 98104, United States

  • The Hope Clinic of the Emory Vaccine Center CRS (Site #31440)

    Decatur, Georgia, 30030, United States

  • University of Pittsburg

    Pittsburgh, Pennsylvania, 15213, United States

Conditions

Explore the condition pages connected to this study.